Article
Drugging RAS: Know the enemy.
Science (New York, N.Y.) - 17 Mar 2017
Papke Bjoern, Der Channing J
Abstract excerpt
The three RAS oncogenes make up the most frequently mutated gene family in human cancer. The well-validated role of mutationally activated RAS genes in driving cancer development and growth has stimulated comprehensive efforts to develop therapeutic strategies to block mutant RAS function for cancer treatment. Disappointingly, despite more than three decades of research effort, clinically effective anti-RAS...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.